Skip to main content Back to Top
Advertisement

6/6/2024

Levofloxacin Injection in 5% Dextrose

Products Affected - Description

    • Levofloxacin in 5% Dextrose intravenous solution for injection, Baxter, 750 mg/150 mL, flexible container, 24 count, NDC 36000-0048-24 - discontinued
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Hikma, 750 mg/150 mL, flexible container, 24 count, NDC 00143-9720-24
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Pfizer, 250 mg/50 mL, flexible container, 24 count, NDC 00409-0528-15
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Pfizer, 500 mg/100 mL, flexible container, 24 count, NDC 00409-0528-25
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Pfizer, 750 mg/150 mL, flexible container, 24 count, NDC 00409-0528-35

Reason for the Shortage

    • Baxter has levofloxacin premixed bags available. The 750 mg/150 mL bags have been discontinued.
    • Hikma did not provide a reason for the shortage.
    • Pfizer states the shortage is due to a manufacturing delay.
    • Sagent has levofloxacin premixed bags available.
    • WG Critical Care has levofloxacin premixed bags available.

Available Products

    • Levofloxacin in 5% Dextrose intravenous solution for injection, Baxter, 250 mg/50 mL, flexible container, 24 count, NDC 36000-0046-24
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Baxter, 500 mg/100 mL, flexible container, 24 count, NDC 36000-0047-24
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Hikma, 250 mg/50 mL, flexible container, 24 count, NDC 00143-9722-24
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Hikma, 500 mg/100 mL, flexible container, 24 count, NDC 00143-9721-24
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Sagent, 250 mg/50 mL, flexible container, 24 count, NDC 25021-0132-81
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Sagent, 500 mg/100 mL, flexible container, 24 count, NDC 25021-0132-82
    • Levofloxacin in 5% Dextrose intravenous solution for injection, Sagent, 750 mg/150 mL, flexible container, 24 count, NDC 25021-0132-83
    • Levofloxacin in 5% Dextrose intravenous solution for injection, WG Critical Care, 250 mg/50 mL, flexible container, 24 count, NDC 44567-0435-24
    • Levofloxacin in 5% Dextrose intravenous solution for injection, WG Critical Care, 500 mg/100 mL, flexible container, 24 count, NDC 44567-0436-24
    • Levofloxacin in 5% Dextrose intravenous solution for injection, WG Critical Care, 750 mg/150 mL, flexible container, 24 count, NDC 44567-0437-24

Estimated Resupply Dates

    • Hikma has levofloxacin 750 mg/150 mL premixed bags on back order and the company estimates a release date of late-July to early-August 2024.
    • Pfizer has levofloxacin 750 mg/150 mL premixed bags on back order and the company estimates a release date of July 2024. The 250 mg/50 mL and 500 mg/100 mL premixed bags are on back order and the company estimates a release date of December 2026. Limited short-dated supply is available for the 250 mg/50 mL premixed bags.

Updated

Updated June 6, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 29, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT